Mycobacterium tuberculosis Dormancy: How to Fight a Hidden Danger
- PMID: 36557586
- PMCID: PMC9784227
- DOI: 10.3390/microorganisms10122334
Mycobacterium tuberculosis Dormancy: How to Fight a Hidden Danger
Abstract
Both latent and active TB infections are caused by a heterogeneous population of mycobacteria, which includes actively replicating and dormant bacilli in different proportions. Dormancy substantially affects M. tuberculosis drug tolerance and TB clinical management due to a significant decrease in the metabolic activity of bacilli, which leads to the complexity of both the diagnosis and the eradication of bacilli. Most diagnostic approaches to latent infection deal with a subpopulation of active M. tuberculosis, underestimating the contribution of dormant bacilli and leading to limited success in the fight against latent TB. Moreover, active TB appears not only as a primary form of infection but can also develop from latent TB, when resuscitation from dormancy is followed by bacterial multiplication, leading to disease progression. To win against latent infection, the identification of the Achilles' heel of dormant M. tuberculosis is urgently needed. Regulatory mechanisms and metabolic adaptation to growth arrest should be studied using in vitro and in vivo models that adequately imitate latent TB infection in macroorganisms. Understanding the mechanisms underlying M. tuberculosis dormancy and resuscitation may provide clues to help control latent infection, reduce disease severity in patients, and prevent pathogen transmission in the population.
Keywords: Mycobacterium tuberculosis; dormancy; latency; persistence; resuscitation; “non-culturability”.
Conflict of interest statement
The author declares that they have no conflict of interest.
Figures
Similar articles
-
Persistent and dormant tubercle bacilli and latent tuberculosis.Front Biosci. 2004 May 1;9:1136-56. doi: 10.2741/1291. Front Biosci. 2004. PMID: 14977534 Review.
-
Mycobacterium tuberculosis transcriptional adaptation, growth arrest and dormancy phenotype development is triggered by vitamin C.PLoS One. 2010 May 27;5(5):e10860. doi: 10.1371/journal.pone.0010860. PLoS One. 2010. PMID: 20523728 Free PMC article.
-
Drug targets in dormant Mycobacterium tuberculosis: can the conquest against tuberculosis become a reality?Infect Dis (Lond). 2018 Feb;50(2):81-94. doi: 10.1080/23744235.2017.1377346. Epub 2017 Sep 21. Infect Dis (Lond). 2018. PMID: 28933243 Review.
-
Mycobacterium dormancy and antibiotic tolerance within the retinal pigment epithelium of ocular tuberculosis.Microbiol Spectr. 2024 Aug 6;12(8):e0078824. doi: 10.1128/spectrum.00788-24. Epub 2024 Jun 25. Microbiol Spectr. 2024. PMID: 38916325 Free PMC article.
-
Dormant non-culturable Mycobacterium tuberculosis retains stable low-abundant mRNA.BMC Genomics. 2015 Nov 16;16:954. doi: 10.1186/s12864-015-2197-6. BMC Genomics. 2015. PMID: 26573524 Free PMC article.
Cited by
-
Molecular and microbiological methods for the identification of nonreplicating Mycobacterium tuberculosis.PLoS Pathog. 2024 Oct 9;20(10):e1012595. doi: 10.1371/journal.ppat.1012595. eCollection 2024 Oct. PLoS Pathog. 2024. PMID: 39383167 Free PMC article. Review.
-
Advancing tuberculosis elimination in India: A qualitative review of current strategies and areas for improvement in tuberculosis preventive treatment.IJID Reg. 2024 Dec 21;14:100556. doi: 10.1016/j.ijregi.2024.100556. eCollection 2025 Mar. IJID Reg. 2024. PMID: 39866845 Free PMC article. Review.
-
Transcriptomic profiling of ceftriaxone-tolerant phenotypes of Neisseria gonorrhoeae reveals downregulation of ribosomal genes - a pilot study.Microbiol Spectr. 2025 Aug 5;13(8):e0120725. doi: 10.1128/spectrum.01207-25. Epub 2025 Jul 7. Microbiol Spectr. 2025. PMID: 40622217 Free PMC article.
-
Drug-Tolerant Mycobacterium tuberculosis Adopt Different Survival Strategies in Alveolar Macrophages of Patients with Pulmonary Tuberculosis.Int J Mol Sci. 2023 Oct 6;24(19):14942. doi: 10.3390/ijms241914942. Int J Mol Sci. 2023. PMID: 37834390 Free PMC article.
-
Repurposing of apoptotic inducer drugs against Mycobacterium tuberculosis.Sci Rep. 2025 Feb 28;15(1):7109. doi: 10.1038/s41598-025-91096-8. Sci Rep. 2025. PMID: 40016256 Free PMC article.
References
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous